outcomes in patients with myelofibrosis: pacritinib vs. bat in the phase iii persist-1 trial
Published 8 years ago • 216 plays • Length 4:56Download video MP4
Download video MP3
Similar videos
-
6:49
hrqol and efficacy in the phase iii persist-1 trial of pacritinib vs bat
-
3:40
persist-1 phase iii study of pacritinib versus bat in pmf, ppv-mf, or pet-mf
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
4:07
safety of full dose pacritinib versus bat in patients with cytopenic myelofibrosis
-
1:21
pacifica: phase iii study of pacritinib vs bat in patients with mf and severe thrombocytopenia
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
1:42
consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
-
2:03
results of the phase 3 persist-1 trial of pacritinib in myelofibrosis
-
5:23
persist-1: pacritinib shakes up the current myelofibrosis treatment landscape
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
4:38
does the patient with myelofibrosis feel better through pacritinib?
-
1:45
results of the phase 3 persist-1 trial of pacritinib for myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
2:48
recent updates on pacritinib in myelofibrosis
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis